[Therapeutic use of thymostimulin in HIV-seropositive subjects and with lymphadenopathy syndrome].
The Authors have carried out a study on the therapeutic effect of thymostimulin in HIV-positive subjects with lymphoadenopathy syndrome. Of the 140 selected patients, 70 were subjected to a treatment with thymostimulin (50 mg/die i.m. for 30 days + 50 mg/3 times a week i.m. in the second, third and fourth month + 50 mg/once a week i.m. in the fifth and sixth month) and of these patients, 60 completed the treatment and the estimated follow-up of twelve months. At the end of this period the following observations were made about the group treated: 1) improvement of the skin reaction to the Multitest (CMI) antigens in 66.7% of the cases, no changes in 30% of the cases and deterioration in 3.3% of the cases; 2) the total T-lymphocytes show an increase in the 6th month, remaining stable for the check-ups of the 9th and 12th months; 3) a significant increase of the CD4 lymphocytes in the 6th month with CD4/CD8 ratio close to the normal values, remaining the same even at the end of the follow-up; 4) during the study none of the treated patients developed opportunistic infections or HIV-related neoplasms. The results were also subjected by the Authors to statistical analyses between the two groups and therefore testify to a favourable effect of thymostimulin with an improvement in the laboratory indications taken into consideration and, above all, the quality of life.